|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||223.20 - 225.00|
|52 Week Range||175.66 - 248.39|
|PE Ratio (TTM)||173.35|
|Earnings Date||Apr 30, 2018 - May 4, 2018|
|Forward Dividend & Yield||3.00 (1.34%)|
|1y Target Est||251.22|
FRANKLIN LAKES, N.J., March 8, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, announced today that it will present at the Barclays Global Healthcare Conference on Wednesday, March 14, 2018, at 1:35 p.m. ET. BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers.
Becton, Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
On February 27, 2018, Abbott Laboratories (ABT) and Surmodics (SRDX) announced that the two companies have entered an agreement for the commercialization rights of Surmodics’ SurVeil DCB (drug-coated balloon) for the treatment of superficial femoral artery. As per the agreement, Abbott Laboratories will gain exclusive commercial rights for the SurVeil DCB, which is currently in clinical trials. Surmodics will supply the device to Abbott once approved.
With a presence across 10 markets, leadership in some segments and a "robust" product pipeline, Becton Dickinson and Co (NYSE: BDX ) is "more than just needles and syringes," according ...
Chimerix (CMRX) makes progress in Q4 through advancement with lead product candidate, brincidofovir. Revenues decline from lower reimbursable expenses regarding BARDA developmental contract.
OPKO Health (OPK) posts lackluster Q4 numbers due to rising operating expenses owing to investments associated with the launch of RAYALDEE and consistent investments in the pharmaceutical pipeline.
New BD Survey Conducted by HIMSS Analytics® Reveals Heightened Need for Seamless Integration of Disparate Technologies during Medication Transit BD HealthSight™ Platform for Enterprise Medication Management ...
Johnson & Johnson (JNJ) began trading ex-dividend on February 26, 2018. It will pay a dividend of $0.84 per share on March 13, 2018, to shareholders of record as of February 26, 2018. Dividend aristocrats are companies that have been paying their shareholders consistently increasing dividends for at least 25 years.
FRANKLIN LAKES, N.J., March 1, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX) announced today the results of its previously announced offer to repurchase (the "Offer") any and all of its outstanding 3.000% Notes due May 15, 2026 (the "Notes") in accordance with the terms and conditions set forth in the offer to repurchase, dated January 8, 2018 (the "Offer to Repurchase"). The Offer expired at 5:00 p.m., New York City time, on March 1, 2018 (the "Expiration Date"). As of the Expiration Date, a total of $460,687,000 aggregate principal amount of Notes were validly tendered and not validly withdrawn, representing approximately 98.04% of the total outstanding aggregate principal amount of Notes. Pursuant to the terms of the Offer, holders who validly tendered and did not validly withdraw their Notes prior to the Expiration Date are entitled to receive cash equal to 101% of the principal amount thereof plus accrued and unpaid interest, if any, to the date of purchase, subject to the rights of holders of Notes on the relevant record date to receive interest due on the relevant interest payment date, which is equivalent to $1,015.58 per $1,000 principal amount of Notes tendered.
Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific
FRANKLIN LAKES, N.J. , Feb. 28, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Raymond James ...
Integra LifeSciences's (IART) solid Q4 revenue growth was primarily driven by high organic revenues and better-than-expected performance by the recently-acquired businesses.